Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabine Kinloch

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
Hepatology (Baltimore, Md.)|April 30, 2024
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responsesBo Sun, Kelly A S da Costa, Aljawharah Alrubayyi, et al.
Gut|December 4, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infectionAnucha Preechanukul, Aljawharah Alrubayyi, Bo Sun, et al.
Medrxiv : the Preprint Server for Health Sciences|April 16, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infectionJay Preechanukul, Aljawharah Alrubayyi, Bo Sun, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profilesEmma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, et al.
Iscience|January 2, 2023
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profilesEmma Touizer, Aljawharah Alrubayyi, Rosemarie Ford, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trialMarcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Hepatology (Baltimore, Md.)|April 30, 2024
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responsesBo Sun, Kelly A S da Costa, Aljawharah Alrubayyi, et al.
Gut|December 4, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infectionAnucha Preechanukul, Aljawharah Alrubayyi, Bo Sun, et al.
Medrxiv : the Preprint Server for Health Sciences|April 16, 2025
Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infectionJay Preechanukul, Aljawharah Alrubayyi, Bo Sun, et al.
Lancet (London, England)|February 23, 2020
Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialSarah Fidler, Wolfgang Stöhr, Matt Pace, et al.
Biorxiv : the Preprint Server for Biology|November 16, 2022
Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profilesEmma Touizer, Aljawharah Alrubbayi, Rosemarie Ford, et al.
Iscience|January 2, 2023
Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profilesEmma Touizer, Aljawharah Alrubayyi, Rosemarie Ford, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trialMarcilio J Fumagalli, Anna Kaczynska, Marius Allombert, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapyMohammed Altaf, Carla Nel, Timothy Tipoe, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO TrialMing Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV|May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trialMing J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Pageof 7